Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Total Current Liabilities: 2010-2025

Historic Total Current Liabilities for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $195.5 million.

  • Arrowhead Pharmaceuticals' Total Current Liabilities rose 89.48% to $195.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $195.5 million, marking a year-over-year increase of 89.48%. This contributed to the annual value of $195.5 million for FY2025, which is 89.48% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Total Current Liabilities stood at $195.5 million for Q3 2025, which was up 0.49% from $194.5 million recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Total Current Liabilities ranged from a high of $220.5 million in Q1 2025 and a low of $63.7 million during Q4 2023.
  • In the last 3 years, Arrowhead Pharmaceuticals' Total Current Liabilities had a median value of $96.7 million in 2024 and averaged $117.8 million.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Total Current Liabilities surged by 446.07% in 2021 and then slumped by 47.77% in 2023.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' Total Current Liabilities stood at $137.0 million in 2021, then declined by 10.96% to $122.0 million in 2022, then tumbled by 47.77% to $63.7 million in 2023, then spiked by 47.13% to $93.8 million in 2024, then skyrocketed by 89.48% to $195.5 million in 2025.
  • Its last three reported values are $195.5 million in Q3 2025, $194.5 million for Q2 2025, and $220.5 million during Q1 2025.